https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — SAN FRANCISCO — Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease control with a novel KRAS G12D inhibitor, a small preliminary study showed.
The early results showed that…
